Mydecine Corrects Financials, Affects Company Valuation

Mydecine Innovations Group, Inc. (TSE:MYCO) has released an update.

Mydecine Innovations Group Inc. has announced a restatement of its 2022 financials due to a valuation error regarding its share transactions and an overlooked asset security agreement. The correction will affect the company’s cash position, increasing debt and expenses. The revised financial statements will be filed later than originally scheduled, replacing the previous inaccurate documents.

For further insights into TSE:MYCO stock, check out TipRanks’ Stock Analysis page.